Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cybin Inc
N.CYBN
Alternate Symbol(s):
CYBN
Healthcare
Drug Manufacturers - Specialty & Generic
Psychedelics
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary...
deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NEO:CYBN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
Next
(2)
•••
Palindrome808
X
Comment by
Palindrome808
on Dec 20, 2024 2:37pm
RE:InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (Cboe
IMO One should hold. Having a viable cure to combat Glaucoma is a gmae changer. Buy more if possbile.
(93)
•••
Tulsa123
X
Post by
Tulsa123
on Aug 21, 2024 7:33am
Vote for holders.
We will be making changes soon once the votes are completed.Hold or not?Good Future.
(93)
•••
Tulsa123
X
Comment by
Tulsa123
on Jun 12, 2024 9:30pm
RE:Today’s news
What do you think?
(93)
•••
Tulsa123
X
Post by
Tulsa123
on Jun 12, 2024 9:29pm
Today’s news
Mushrooms used soon for suicidal migraines causes.interesting
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 18, 2024 7:33am
New Press Release - Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
- Publication explores structure-activity relationships (“SAR”) of a broad range of 2C-X analogs -- Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist with favorable pharmacokinetic properties - Cybin Inc. (NYSE American:CYBN) (Cboe...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 16, 2024 7:34am
New Press Release - Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
- Newly issued patent expected to provide exclusivity until at least 2041 and includes claims to pharmaceutical compositions within the Company’s proprietary deuterated psilocybin analog program -- Cybin’s patent portfolio now includes more than 50 granted patents and over 170 pending...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Apr 10, 2024 7:30am
New Press Release - Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that Doug Drysdale, Cybin’s...
read article.
(89)
•••
Tardis
X
Post by
Tardis
on Apr 08, 2024 8:40am
Globe says MindMed, Cybin get nod from U.S. FDA
2024-04-08 07:12 ET - In the News See In the News (C-MMED) Mind Medicine (MindMed) Inc (2) The Globe and Mail reports in its Monday edition that psychedelic drugs are making progress toward being
...more
(89)
•••
Tardis
X
Post by
Tardis
on Mar 19, 2024 2:57pm
Very Smart Money Bought In
Buy on any weakness IMO. This sector is and will continue to recieve serious attention. Cybin will be the belle of the ball IMHO. Tight Lines Gilly Cybin closes $150-million (U.S
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 19, 2024 11:53am
New Press Release - Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company...
read article.
(89)
•••
Tardis
X
Post by
Tardis
on Mar 18, 2024 7:51am
Cybin To Present
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas 2024-03-18 07:30 ET - News Release
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 18, 2024 7:31am
New Press Release - Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the upcoming...
read article.
(89)
•••
Tardis
X
Post by
Tardis
on Mar 15, 2024 8:34am
Phase 2 Proof Of Concept
https://ir.cybin.com/investors/news/news-details/2024/Cybin-Initiates-Phase-2-Proof-of-Concept-Study-of-CYB004-in-Generalized-Anxiety-Disorder/default.aspx Tight Lines Gilly
(89)
•••
Tardis
X
Post by
Tardis
on Mar 14, 2024 7:21pm
CYBIN CEO Doug Drysdale Interview
https://www.youtube.com/watch?v=qZWGF2M4vwE Tight Lines Gilly
(89)
•••
Tardis
X
Post by
Tardis
on Mar 14, 2024 8:54am
News - Positive end of phase 2
https://ir.cybin.com/investors/news/news-details/2024/Cybin-Announces-Positive-End-of-Phase-2-Meeting-with-FDA-for-CYB003-in-Major-Depressive-Disorder-and-Phase-3-Program-Design/default.aspx Tight
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >